1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - Any purpose.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [ashish.dtk@gmail.com].
   


6. For how long will this data be available start date provided 01-01-2024 and end date provided 31-12-2029?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - Nil

The patient’s quality of life is significantly negatively impacted by chronic tonsillitis. Chronic tonsillitis is said to benefit from homeopathic medicines, however there is currently inadequate evidence to support this claim. We evaluated the efficacy of individualized homeopathic medicines (IHMs) in treating chronic tonsillitis in adults in comparison with placebos. In this 3-month, double-blind, randomized (1:1), placebo-controlled trial, 60 adult patients with chronic tonsillitis were randomized to receive either IHMs or identical-looking placebos. Conventional management was advised concurrently to all individuals. The primary outcome was disease severity using the visual analogue scale (VAS) scores of sore throat pain model (STPM) comprising of the sore throat pain intensity VAS (STPIS-VAS), difficulty swallowing scale VAS (DSS-VAS), and swollen throat scale VAS (SWOTS-VAS); secondary outcomes were the Tonsil and adenoid health status instrument (TAHSI) scores and Glasgow benefit inventory (GBI) scale – all measured at baseline, and every month, up to 3 months. Group differences were calculated on the intention-to-treat sample using unpaired t-tests primarily, and two-ways repeated measure analysis of variance secondarily. After 3 months of intervention, inter-group differences became statistically significant favoring IHMs against placebos on STPIS-VAS (mean difference: -1.2, 95% CI -1.8 to -0.7, P < 0.001, d = 1.142), DSS-VAS (mean difference: -1.3, 95% CI -1.9 to -0.7, P < 0.001, d = 1.129), and SWOTS-VAS (mean difference: -1.4, 95% CI -2.0 to -0.8, P < 0.001, d = 1.167). Secondary outcomes also revealed significance favoring homeopathy over placebo after 3 months – TAHSI (mean difference: -13.1, 95% CI -20.3 to -5.9, P < 0.001, d = 0.943), and GBI (mean difference: -10.6, 95% CI -16.3 to -4.9, P < 0.001, d = 0.967). TAHSI subscales and GBI subscales also yielded similar significant results. Secondary analyses failed to demonstrate any significant effect on the primary outcome, but showed significance on the secondary outcomes and in most of the subscales. Thus, IHMs considerably outperformed placebos in the treatment of adult patients with chronic tonsillitis.